Completion of Fund Raising

Proteome Sciences PLC
4 October 2001

                                PRESS RELEASE


4th October, 2001



                    PROTEOME SCIENCES ANNOUNCES SUCCESSFUL


                   COMPLETION OF INTRONN INC. FUND-RAISING



Following the Interim Statement released on 28th September, 2001, Proteome
Sciences plc (Proteome Sciences) is pleased to announce that Intronn Inc. has
completed its US $7m funding, the proceeds of which have now been received.
Intronn Inc is a new company which has been formed specifically to develop and
exploit the SMaRTTM modification of gene expression technology developed by
Intronn LLC. With the funding in place, there will be no recourse to Proteome
Sciences for further funding of the SMaRTTM programmes.


The other activities of Intronn LLC that were unrelated to SMaRTTM have been
transferred into a new corporation, Veri-Q Inc. These assets include the
projects in synthetic oligonucleotides and the standardization and quality
control markers. Proteome Sciences has a 55% equity interest in Veri-Q Inc.
and proposes forthwith to actively pursue licensing partners to commercialise
the technologies.




                                     ENDS


For further information please contact:

Proteome Sciences plc       Tel: [phone]

Christopher Pearce, Chief Executive   E-mail : [e-mail]

Public Relations

Ikon Associates

Adrian Shaw   Tel: [phone] Mobile: [phone]

E-mail:[e-mail]